論文

査読有り 国際誌
2021年6月

Development of Anti-Human CC Chemokine Receptor 9 Monoclonal Antibodies for Flow Cytometry.

Monoclonal antibodies in immunodiagnosis and immunotherapy
  • Ren Nanamiya
  • ,
  • Junko Takei
  • ,
  • Teizo Asano
  • ,
  • Tomohiro Tanaka
  • ,
  • Masato Sano
  • ,
  • Takuro Nakamura
  • ,
  • Miyuki Yanaka
  • ,
  • Hideki Hosono
  • ,
  • Mika K Kaneko
  • ,
  • Yukinari Kato

40
3
開始ページ
101
終了ページ
106
記述言語
英語
掲載種別
研究論文(学術雑誌)
DOI
10.1089/mab.2021.0007

CC chemokine receptor 9 (CCR9) belongs to the beta chemokine receptor family and is mainly distributed on the surface of immature T lymphocytes and enterocytes. This receptor is highly expressed in rheumatoid arthritis, colitis, type 2 diabetes, and various tumors. Therefore, more sensitive monoclonal antibodies (mAbs) need to be developed to predict the prognosis of many high CCR9 expression diseases. Because CCR9 is a structurally unstable G protein-coupled receptor, it has been difficult to develop anti-CCR9 mAbs using the traditional method. This study developed anti-human CCR9 (hCCR9) mAbs for flow cytometry using a Cell-Based Immunization and Screening (CBIS) method. Two mice were immunized with hCCR9-overexpressed Chinese hamster ovary (CHO)-K1 cells (CHO/hCCR9), and hybridomas showing strong signals from CHO/hCCR9 and no signals from CHO-K1 cells were selected by flow cytometry. We established an anti-hCCR9 mAb, C9Mab-1 (IgG1, kappa), which detected hCCR9 in MOLT-4 leukemia T lymphoblast cells and CHO/hCCR9 cells by flow cytometry. Our study showed that an anti-hCCR9 mAb was developed more rapidly by the CBIS method than the previous method.

リンク情報
DOI
https://doi.org/10.1089/mab.2021.0007
PubMed
https://www.ncbi.nlm.nih.gov/pubmed/34161159
ID情報
  • DOI : 10.1089/mab.2021.0007
  • PubMed ID : 34161159

エクスポート
BibTeX RIS